There is no single answer, because melanoma’s timeline depends almost entirely on when it’s caught. A melanoma found early, while it’s still confined to the skin, has a five-year survival rate of virtually 100%. A melanoma that has already spread to distant organs has a five-year survival rate of 34%, though modern treatments have pushed median survival for those patients from about six months to over six years in the past decade alone. The gap between those numbers is enormous, and it explains why stage matters more than almost anything else.
Stage at Diagnosis Changes Everything
Melanoma is grouped into three broad categories based on how far it has spread. The survival statistics for each tell a dramatically different story.
- Localized (still in the skin): Five-year relative survival is 100%. The vast majority of melanomas are caught at this stage, and for most of these patients, surgical removal is curative.
- Regional (spread to nearby lymph nodes): Five-year relative survival drops to 76%. This means the cancer has moved beyond the original spot but hasn’t reached distant organs.
- Distant (metastatic, spread to other organs): Five-year relative survival is 34%. This is the stage people are usually thinking about when they search for how quickly melanoma can kill.
These numbers come from the National Cancer Institute’s SEER database and reflect patients diagnosed between 2016 and 2022. They’re population averages. Individual outcomes vary based on tumor thickness, location, genetic mutations in the cancer, age, and how well someone responds to treatment.
How Fast Untreated Melanoma Progresses
Without any treatment, metastatic melanoma historically killed within six to eight months of diagnosis. That was the reality as recently as 2011, when median survival for stage IV patients was just six and a half months. Some patients lived longer, some shorter, but the disease moved fast once it reached organs like the liver, lungs, or brain.
A thin melanoma on the skin, left completely alone, can take months to years before it invades deeply enough to spread. The trouble is that once it does breach into deeper tissue and enters the bloodstream or lymphatic system, the timeline accelerates sharply. There’s no reliable way to predict exactly when a melanoma will cross that threshold, which is why early removal matters so much.
Modern Treatment Has Changed the Timeline
The survival landscape for metastatic melanoma shifted dramatically after 2011 with the introduction of immunotherapy drugs that help the immune system recognize and attack cancer cells. For patients treated with a combination immunotherapy regimen, median survival has climbed from six and a half months to a little over six years, according to long-term data from the landmark CheckMate 067 trial reported by Dana-Farber Cancer Institute. That’s a tenfold improvement in just over a decade.
Not everyone responds equally. Some patients achieve durable remissions lasting many years. Others see initial improvement followed by progression. Targeted therapies for melanomas with specific genetic mutations offer another option, with strong initial responses though sometimes shorter durability than immunotherapy.
The 34% five-year survival rate for distant melanoma reflects a mix of patients: those who responded well, those who didn’t, and those diagnosed before the newest treatments were widely available. If you’re being treated today with current therapies, your individual odds may be better than that population average suggests.
Where Melanoma Spreads and Why It Matters
Melanoma tends to spread first to nearby skin and lymph nodes, then to the lungs, liver, brain, and bones. Where it lands affects both symptoms and prognosis. Brain metastases have historically carried the worst outlook, with a median survival of roughly four months before modern immunotherapy. Newer combination treatments have pushed that figure significantly higher, with some studies reporting median survival of three years for brain metastasis patients on combination immunotherapy.
Lung metastases generally carry a somewhat better prognosis than brain or liver involvement, partly because they’re often detected earlier on imaging and may respond better to systemic treatment.
When Recurrence Is Most Likely
If you’ve had a melanoma removed and are wondering about the risk going forward, the highest-risk window is the first three years. About 80% of all melanoma recurrences happen within that period. The risk peaks around one year after diagnosis. Local and lymph node recurrences tend to show up earliest, around eight months, while spread to distant sites like the lungs peaks closer to two years out.
This doesn’t mean you’re safe after three years. Late recurrences, sometimes five or even ten years later, do happen with melanoma more than with many other cancers. But the probability drops substantially with each passing year, and most people who reach the five-year mark without recurrence stay disease-free.
What the Final Stage Looks Like
For patients whose melanoma doesn’t respond to treatment or who choose to stop treatment, the final weeks follow a pattern common to many advanced cancers. Energy drops progressively. Appetite fades, often starting weeks before the end. Sleep increases, and periods of confusion or disorientation become more frequent. Some people experience a brief window of mental clarity before declining again.
In the last days, circulation slows. Hands and feet may feel cool and look mottled or bluish. Breathing patterns become irregular, sometimes speeding up and then slowing. Mucus can collect in the throat, causing a rattling sound with each breath. Most people lose consciousness before death, though hearing is thought to persist even after someone can no longer speak or respond.
The pace of this decline varies widely. Some people transition from active daily life to death in a matter of days. Others experience a gradual decline over weeks. There is no fixed timeline for this final phase, and predicting it precisely is not something even experienced clinicians can do reliably.
The Factors That Shape Your Timeline
Several things influence how long someone lives with melanoma beyond just the stage:
- Tumor thickness at diagnosis: Thinner melanomas (under 1 mm) that haven’t ulcerated have excellent outcomes. Thicker tumors carry higher risk of spread even after removal.
- Ulceration: A melanoma that has broken through the skin surface is more aggressive than one that hasn’t, even at the same thickness.
- Genetic mutations: About half of melanomas carry a specific mutation that makes them eligible for targeted therapy, which can produce rapid responses.
- Location of metastases: Skin and lung metastases generally have better outcomes than brain or liver involvement.
- Response to immunotherapy: Patients who respond to immunotherapy in the first few months tend to have significantly longer survival, and some achieve what appears to be a functional cure.
Age and overall health also play a role. Younger patients and those without other serious medical conditions tend to tolerate aggressive treatment better and often have stronger immune responses to immunotherapy.